1Agarwal SK,Avery CL,Ballantyne CM,et al.Sources of variability in measurements of cardiac troponin T in a community-based sample:the atherosclerosis risk in communities study.Clin Chem,2011,57:891-897.
2Boekholdt SM,Arsenault BJ,Mora S,et al.Association of LDL cholesterol,non-HDL cholesterol,and apolipoprotein.B levels with risk of cardiovascular events among patients treated with statins:a meta-analysis.JAMA,2012,307:1302-1309.
3Sniderman AD,Williams K,Contois JH,et al.A meta-analysis of lowdensity lipoprotein cholesterol,non-highdensity lipoprotein cholesterol,and apolipoprotein B as markers of cardiovascular risk.Circ Cardiovasc Qual Outcomes,2011,4:337-345.
4Baigent C,Keech A,Kearney PM,et al.Cholesterol Treatment Trialists’(CTT)Collaborators.Efficacy and safety of cholesterol-lowering treatment:prospective meta-analysis of data from 90,056 participants in 14randomised trials of statins.Lancet,2005,366:1267-1278.
5Genser B,Marz W.Low density lipoprotein cholesterol,statins and cardiovascular events:a meta-analysis.Clin Res Cardiol,2006,95:393-404.
6Avis HJ,Hutten BA,Gagne C,et al.Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.J Am Coll Cardiol,2010,55:1121-1126.
7Seidah NG,Prat A.Precursor convertases in the secretory pathway,cytosol and extracellular milieu.Essays Biochem,2002,38:79-94.
9Naureckiene S,Ma L,Sreekumar K,et al.Functional characterization of Narc 1,a novel proteinase related to proteinase K.Arch Biochem Biophys,2003,420:55-67.
10Benjannet S,Rhainds D,Essalmani R,et al.NARC-1/PCSK9 and its natural mutants:zymogen cleavage and effects on the lowdensity lipoprotein(LDL)receptor and LDL cholesterol.J Biol Chem,2004,279:48865-48875.
